for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

TORII PHARMACEUTICAL CO., LTD.

4551.T

Latest Trade

2,791.00JPY

Change

1.00(+0.04%)

Volume

53,600

Today's Range

2,777.00

 - 

2,801.00

52 Week Range

2,067.00

 - 

3,035.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Japan Tobacco Inc - Transfer Date Of Marketing Approvals Of 6 Anti-Hiv Drugs To Gilead Sciences Kk Set For Dec. 1

Japan Tobacco Inc <2914.T>::JAPAN TOBACCO INC - TRANSFER DATE OF MARKETING APPROVALS OF 6 ANTI-HIV DRUGS TO GILEAD SCIENCES KK SET FOR DEC. 1.

Japan Tobacco Top-Line Results Of Phase 3 Clinical Studies Of JTZ-951 In Anemic Patients With Chronic Kidney Disease In Japan

July 12 (Reuters) - Japan Tobacco Inc <2914.T>::TOP-LINE RESULTS OF PHASE 3 CLINICAL STUDIES OF JTZ-951 IN ANEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE IN JAPAN.RESULTS SHOW BOTH STUDIES MET PRIMARY ENDPOINTS.JT AND TORII <<<4551.T>>> WILL AIM TO SUBMIT MARKETING APPLICATION FOR JTZ-951 IN JAPAN BASED ON RESULTS OF THIS AND OTHER CLINICAL STUDIES.

Torii Pharmaceutical Co Goichi Matsuda To Be President Effective March 26

Torii Pharmaceutical Co Ltd <4551.T>::GOICHI MATSUDA TO BE PRESIDENT EFFECTIVE MARCH 26.

Torii Pharmaceutical says new drug application approval of allergen immunotherapy tablet for japanese cedar pollinosis

Sept 27 (Reuters) - Torii Pharmaceutical Co Ltd <4551.T>:* Says the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of "CEDARCURE® Japanese Cedar Pollen Sublingual Tablets", an allergen immunotherapy tablet for Japanese cedar pollinosis .

Menlo Therapeutics signs license agreement with Japan Tobacco, Torii Pharma for NK-1 receptor antagonist

Menlo Therapeutics Inc : Menlo Therapeutics signs exclusive license agreement with Japan Tobacco and Torii Pharmaceuticals for development and commercialization of NK-1 receptor antagonist in Japan . Entered into license agreement with Japan Tobacco Inc. and Torii Pharmaceutical for development,commercialization of serlopitant in Japan .JT,Torii to pay co upfront licensing fees,payments upon achievement of certain milestones, royalties based on future sales in Japan.

Torii Pharmaceutical raises consolidated full-year outlook for FY 2015

Torii Pharmaceutical Co Ltd:Says the company increased the consolidated full-year outlook for revenue to 62,370 mln yen from 61,300 mln yen, for the fiscal year ending Dec. 31, 2015.Operating profit forecast increased to 4,910 mln yen from 4,000 mln yen.Ordinary profit forecast increased to 5,130 mln yen from 4,200 mln yen.Net profit forecast increased to 3,520 mln yen from 2,600 mln yen.Earnings per share increased to 124.38 yen from 91.87 yen.Comments the increased sales of core products and cost control are the main reasons for the forecast.

Torii Pharmaceutical files New Drug Application for TO-206

Torii Pharmaceutical Co Ltd:Filed a New Drug Application for TO-206, an allergen immunotherapy tablet for Japanese cedar pollinosis to the Japanese Ministry of Health, Labour and Welfare.

Torii Pharmaceutical announces new drug approval in Japan

Torii Pharmaceutical Co Ltd:Obtained the marketing approval of MITICURE® House Dust Mite Sublingual Tablets (“MITICURE” hereinafter), an allergen immunotherapy tablet for house dust mite allergy, for the indication of allergic rhinitis. in Japan.

Japan Tobacco signs contract of selling right of 2 new anti-HIV drugs with Torii Pharmaceutical

Japan Tobacco Inc:Signed an exclusive distribution agreement in Japan of 2 new anti-HIV drugs with Torii Pharmaceutical Co., Ltd.

Japan Tobacco Inc AND Torii Pharmaceutical Co., Ltd launches Riona tablets

Japan Tobacco Inc:Torii Pharmaceutical Co., Ltd and Japan Tobacco Inc (JT) announces that Torii would launch Riona tablets 250mg in Japan on May 12.Says it receives manufacturing and marketing approval of this drug for the indication of the improvement of hyperphosphatemia in patients with chronic kidney disease (CKD) from the Japanese Ministry of Health, Labour and Welfare in Jan 2014.JT and Torii expect to contribute to treat hyperphosphatemia in patients with CKD, including dialysis and non-dialysis dependent CKD, through marketing Riona tablets in Japan.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up